Doug Harper, having signed the purchase agreement for PSSI between them and Candela, was the only person with whom I spoke that had anything necessarily positive to say about Candela. Others with whom I spoke were very doubtful of Candela's long term success as well as the truthfulness of management. Dr. Richard Sharpe has collected evidence with which he wishes to sue Candela for anti-trust violations regarding the sale of Cryogen. The company has introduced a plethora of products all targeted to the market of dermatology and cosmetic surgery. Products have historically been rendered obsolete by competitive technologies.
Candela seems to have a tough time holding on to talent.
Evidently there are many people at Coherent and Cynassure that used to work for Candela. 1.5 million shares were offered by the company while the remainder was offered by Signatronics Asset Holdings. The largest holder of management is Robert Dornbush, an outside director. Growth Prospects . Drivers of growth over the near term are to be sales of the GentleLASE, as well as the GentleLASE Plus recently announced on September 22 nd .